Masthead small

Hepatitis B in pregnancy: screening, treatment, and prevention of vertical transmission


  • The diagnosis of the chronic carrier state is confirmed with persistence of HBsAg and the absence of hepatitis B surface antibody (HBsAb).
  • HBsAg and HBsAb do not coexist.
  • Start with maternal HBsAg.
  • HBV core ab is produced secondary to infection (never from immunization).


In the United States, vertical transmission is responsible for up to 50% of HBV infection worldwide.o In pregnancy, prevalence 0.7-0.9% for chronic HBV



  • HBV viral load in the third trimester (28-32 weeks)
  • If> 6-8 log 10 copies /mL – antiretroviral Rx to decrease risk of intrauterine transmission
  • To convert viral load from IU/mL to copies /mL multiply x5.6
  • Tenofovir (first line) 300 mg/day till delivery
  • Lamivudine (high rate of resistance) if used as a single agent
  • Indications for antiretroviral: Copies > 106-8; Pos HBeAg
  • The use of lamivudine and tenofovir in the postpartum period is not currently recommended solely for HBV prevention until additional data are available.